Revance Files $86.25 Million IPO

Published: Jan 03, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Revance Therapeutics, Inc. (Nasdaq: RVNC) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the symbol "RVNC."

Help employers find you! Check out all the jobs and post your resume.

Back to news